The VPC's My Precision Oncology Program (MyPOP) is the lead story in the Nov. 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. The article includes an interview with Dr. Kim Chi, Associate Director of Clinical Research at our Centre. Read the full article here (opens in new window).
OncoGenex Pharmaceuticals Inc. has announced positive survival results from the final analysis of the Apatorsen Phase 2 Borealis-2™ trial in metastatic bladder cancer. Apatorsen (OGX-427) was discovered at the VPC and outlicensed to OncoGenex. The full press release is below; click here for the original article on PR Newswire (opens in new window).
May 18, 2016, Vancouver, B.C – BGI, headquartered in China, and the Vancouver Prostate Centre (VPC) signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC.
The Networks of Centres of Excellence (NCE) of Canada published an impact story about the recent licensing agreement between Roche and UBC. It describes PC-TRiADD's role in assisting the transition from discovery to intellectual property (IP) to commercialization.
Click here to read the article at the NCE's website.
A potential treatment for advanced prostate cancer developed by the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.
Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.
This new approach, which halted the growth of various tumours in mice, was based on a discovery by collaborators at the University of Copenhagen. While exploring why pregnant women are particularly susceptible to malaria, they found that the mosquito-borne parasite produces a protein that binds to a particular type of sugar molecule in the placenta.
September 26, 2014 - Prostate Cancer Canada today annouced the results of their funding decision in their Translation Acceleration Grant competition TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men. Co-lead by Drs.
SHENZHEN, China and VANCOUVER, British Columbia, September 12, 2014 – BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre (VPC), a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including precision oncology.
With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.The Accel-Rx Health Sciences Accelerator is a national organization focused on maximizing new health sciences company creation, and ensuring start-ups have the resources they need to enable them to stay and grow in Canada and give rise to a new gen